Active ingredient: Clevidipine butyrate emulsion 0.5 mg/mL; solution for IV infusion; contains lipids 0.2 g/mL (soybean oil, egg phospholipids). Indication: To reduce BP when oral therapy is not ...
New research has identified the specific biological mechanism behind the muscle dysfunction found in myotonic dystrophy type 1 (DM1) and further shows that calcium channel blockers can reverse these ...
Praxis Precision Medicines' ulixacaltamide (PRAX-944) is a potent and selective small molecule T-type Ca2+ channel blocker being developed for the potential treatment of essential tremor. ET is a ...
Toxicity due to calcium-channel blockers (CCBs) or β-blockers results in significant morbidity and mortality. [9] The manifestations of toxicity are generally extensions of the drugs' pharmacologic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback